Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (P) and standard platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) (AFT-09).

Authors

Thomas A. Hensing

NorthShore University Health System/University of Chicago, Evanston, IL

Thomas A. Hensing , Xiaofei F. Wang , Junheng Gao , Tom Stinchcombe , Michael V. Knopp , Arkadiusz Z. Dudek , Stephen L. Graziano , Jyoti D. Patel , Bryan Faller , Konstantin H. Dragnev , David E. Kozono , Everett E. Vokes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non–small cell lung cancer (NSCLC).

First Author: Edward B. Garon

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non–small-cell lung cancer (NSCLC): LEAP-006.

First Author: Rina Hui

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%.

First Author: Melissa Lynne Johnson

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC).

First Author: Nicholas Coupe